OralDosed ingredient Cosmetic cross-reference

Niacin

CAS 59-67-6

Niacin (CAS 59-67-6) is a Phase 4 pharmaceutical compound with 6 bioactivity targets and 1,170 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
16
SOURCE DrugCentral
Adverse signals
1,170
SOURCE IUPHAR/BPS
PubMed IDs
5
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Niacin
CAS Number
59-67-6
UNII
2679MF687A
InChIKey
PVNIIMVLHYAWGP-UHFFFAOYSA-N
ChEMBL ID
CHEMBL573
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
Niaspan
dosed ingredientnatural productoral
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL573 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE EMBL-EBI ChEMBL 16 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- AC50 21898.43950617284 nM 81 -
- EC50 2687.961875 nM 45 -
- IC50 6423.159310344828 nM 28 -
- Potency 20705.693333333336 nM 14 -
- Ki 67.25 nM 4 -
- MIC 96 ug.mL-1 2 -
- IC50 41.25 ug.mL-1 1 -
- Kd 1400 nM 1 -
Hydroxycarboxylic acid receptor 3
GPCR
 EC50 6.52 - Homo sapiens
Nicotinamide N-methyltransferase
Enzyme
 - - - Homo sapiens
Nicotinate-nucleotide pyrophosphorylase [carboxylating]
Enzyme
 - - - Homo sapiens
Nicotinamide phosphoribosyltransferase
Enzyme
 - - - Homo sapiens
Hydroxycarboxylic acid receptor 2
GPCR
 Ki 7.48 - Rattus norvegicus
Hydroxycarboxylic acid receptor 2
GPCR
 IC50 6.85 - Mus musculus
Amyloid beta A4 protein
Unclassified
 IC50 4.88 - Homo sapiens
Hydroxycarboxylic acid receptor 2
GPCR
 Ki 7.3 - Homo sapiens
SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Flushing 869 1022.336 10016825
Off label use 535 282.215 10053762
Product residue present 124 228.839 10081359
Contraindicated product administered 17 215.018 10078504
Pemphigus 3 200.888 10034280
Synovitis 6 198.055 10042868
Product use in unapproved indication 51 194.191 10076476
Hand deformity 3 173.17 10061194
Completed suicide 23 173.035 10010144
Treatment failure 37 169.062 10066901
Systemic lupus erythematosus 25 163.095 10042945
Infusion related reaction 76 157.327 10051792
Toxicity to various agents 156 152.087 10070863
Drug abuse 7 145.902 10013654
Product use issue 73 143.883 10076309
Maternal exposure during pregnancy 38 140.593 10071408
Glossodynia 25 132.668 10018388
Skin burning sensation 122 128.698 10054786
Drug ineffective 1028 127.499 10013709
Muscle spasms 519 123.597 10028334
Product dose omission issue 699 121.649 10084406
Drug intolerance 139 120.905 10061822
Myalgia 505 107.177 10028411
Pruritus 902 105.366 10037087
Pericarditis 20 101.522 10034484
General physical health deterioration 116 101.096 10049438
Diarrhoea 1668 100.086 10012735
High density lipoprotein decreased 67 100.07 10020060
Therapy cessation 175 97.373 10065154
Fall 971 89.047 10016173
Lower respiratory tract infection 36 86.169 10024968
Wound 48 85.334 10052428
Dizziness 1036 81.041 10013573
Duodenal ulcer perforation 6 80.124 10013849
Intentional product use issue 75 77.383 10076308
Asthenia 989 76.445 10003549
Plasma cell myeloma 208 72.822 10035226
Full blood count decreased 144 72.413 10017413
Blood glucose increased 318 67.709 10005557
Helicobacter infection 14 67.588 10054263
Paraesthesia 425 66.86 10033775
Condition aggravated 381 66.215 10010264
Rheumatoid arthritis 141 66.003 10039073
Therapeutic product effect incomplete 57 65.894 10082200
Muscle injury 3 63.836 10028314
Psoriasis 273 61.747 10037153
Low density lipoprotein increased 66 60.71 10024910
Drug hypersensitivity 667 59.158 10013700
Feeling hot 183 57.83 10016334
Arthropathy 130 57.513 10003285

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE IUPHAR/BPS 3 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

TargetAction AffinityPubMed
HCA 1 receptor
HCAR1
 Agonist - 12522134
HCA 2 receptor
HCAR2
 Full agonist 6.0 pEC50 12522134|12563315|12646212
HCA 3 receptor
HCAR3
 Full agonist 4.0 pEC50 12522134
SOURCE PharmGKB 4 phenotype rows

Pharmacogenomics

Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.

HCAR2 (PA165961843) rs7314976
Genotypes AA + AG is not associated with response to niacin as compared to genotype GG.
Evidence: -; PMID 28628560
HCAR2 (PA165961843) rs2454727
Genotypes CT + TT is associated with decreased response to niacin as compared to genotype CC.
Evidence: -; PMID 28628560
NR1H3 (PA31751) rs2279238
Genotype TT is associated with increased severity of Flushing when treated with laropiprant and niacin in people with Dyslipidaemia or Hypercholesterolemia as compared to genotype CC.
Evidence: -; PMID 26226939
HCAR2 (PA165961843) rs2454727
Genotypes CT + TT is not associated with response to niacin as compared to genotype CC.
Evidence: -; PMID 28628560
SOURCE NLM RxNorm 5 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
niacin 7393 SU MTHSPL
NIACIN 7393 SU MTHSPL
Niacin 7393 SU MTHSPL
niacin 7393 IN RXNORM
Niaspan 346366 BN RXNORM
SOURCE SIDER 80 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side EffectDrug Name MedDRA TypeConcept ID
Abdominal distension niacin PT C0000731
Abdominal pain niacin LLT C0000737
Abdominal pain niacin PT C0000737
Abnormal vision niacin LLT C3665386
Acanthosis nigricans niacin LLT C0000889
Acanthosis nigricans niacin PT C0000889
Alopecia niacin LLT C0002170
Alopecia niacin PT C0002170
Amblyopia niacin LLT C0002418
Amblyopia niacin PT C0002418
Anaphylactic shock niacin LLT C0002792
Anaphylactic shock niacin PT C0002792
Angina pectoris niacin LLT C0002962
Angina pectoris niacin PT C0002962
Angioedema niacin LLT C0002994
Angioedema niacin PT C0002994
Angiopathy niacin LLT C0042373
Angiopathy niacin PT C0042373
Anorexia niacin LLT C0003123
Application site reaction niacin LLT C0151505
Application site reaction niacin PT C0151505
Arrhythmia niacin LLT C0003811
Arrhythmia niacin PT C0003811
Arterial thrombosis niacin PT C0151942
Arthralgia niacin LLT C0003862
Arthralgia niacin PT C0003862
Arthritis niacin LLT C0003864
Arthritis niacin PT C0003864
Ascites niacin LLT C0003962
Ascites niacin PT C0003962
Asthenia niacin LLT C0004093
Asthenia niacin PT C0004093
Atherothrombosis niacin LLT C1963943
Atrial fibrillation niacin LLT C0004238
Atrial fibrillation niacin PT C0004238
Blood glucose increased niacin LLT C0595877
Blood glucose increased niacin PT C0595877
Blood insulin increased niacin PT C0852795
Blood uric acid increased niacin PT C0235416
Body temperature increased niacin LLT C0015967
Body temperature increased niacin PT C0015967
Bone disorder niacin LLT C0005940
Bone disorder niacin PT C0005940
Breast pain niacin LLT C0024902
Breast pain niacin PT C0024902
Bronchitis niacin LLT C0006277
Bronchitis niacin PT C0006277
Burning sensation niacin LLT C0085624
Burning sensation niacin PT C0085624
Bursitis niacin LLT C0006444
Bursitis niacin PT C0006444
Chills niacin LLT C0085593
Chills niacin PT C0085593
Cholelithiasis niacin LLT C0008350
Cholelithiasis niacin PT C0008350
Cholestasis niacin LLT C0008370
Cholestasis niacin PT C0008370
Cough niacin LLT C0010200
Cough niacin PT C0010200
Cough niacin PT C0010200
Cough increased niacin LLT C0574067
Cramps of lower extremities niacin LLT C0023218
Cystoid macular oedema niacin LLT C0024440
Cystoid macular oedema niacin PT C0024440
Decreased appetite niacin PT C0232462
Dermatitis niacin PT C0011603
Dermatitis bullous niacin PT C0085932
Dermatitis contact niacin LLT C0011616
Dermatitis contact niacin PT C0011616
Diabetes mellitus niacin LLT C0011849
Diabetes mellitus niacin PT C0011849
Diarrhoea niacin LLT C0011991
Diarrhoea niacin PT C0011991
Disturbance in sexual arousal niacin PT C0855242
Dizziness niacin LLT C0012833
Dizziness niacin PT C0012833
Dizziness niacin PT C0012833
Dry mouth niacin LLT C0043352
Dry mouth niacin PT C0043352
Dry skin niacin LLT C0151908
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Niacin used for in pharmaceutical contexts?

Niacin (CAS 59-67-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Niacin?

Niacin has 1,170 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Flushing, Off label use, Product residue present, Contraindicated product administered, Pemphigus. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Niacin also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for NIACIN with EU status "permitted".

What clinical phase is Niacin in?

Niacin is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Niacin?

Niacin has 16 bioactivity rows in this page query. Rendered target entries include Hydroxycarboxylic acid receptor 3, Nicotinamide N-methyltransferase, Nicotinate-nucleotide pyrophosphorylase [carboxylating], Nicotinamide phosphoribosyltransferase, Hydroxycarboxylic acid receptor 2.